Distribution of γδ T cells in patients with hematological malignancies

Published: June 8, 2009
Abstract Views: 164
PDF: 129
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Tumor progression in multiple myeloma (MM) is due to intrinsic features of myeloma cells and to interactions of myeloma cells with the bone marrow microenvironment. Beside promoting myeloma cell survival and proliferation, these interactions are responsible for: 1) the activation and differentiation of osteoclast precursors into mature osteoclasts, yielding to bone resorption and lytic lesions, 2) the angiogenic switch sustained by endothelial cells and other stromal cells, via paracrine and autocrine loops, involving multiple VEGF/VEGF-R and other pathways; 3) a progressive immune failure that is responsible for the enhanced susceptibility to infections of MM patients and the escape of myeloma cells to host immune surveillance.

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Supporting Agencies

How to Cite

Mariani, S., Pantaleoni, F., & Peola, S. (2009). Distribution of γδ T cells in patients with hematological malignancies. Hematology Meeting Reports (formerly Haematologica Reports), 2(3). https://doi.org/10.4081/hmr.v2i3.368